Amir Ghahfarokhi-Taheri
BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing.
Journal: Nature communications
Published: January 26, 2023
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo.
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo.
Journal: Nature communications
Published: October 03, 2022
Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: June 13, 2022
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery.
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery.
Journal: Nature communications
Published: March 23, 2020
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
Journal: BMC biology
Published: October 22, 2018
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Journal: Oncotarget
Published: February 05, 2018
NKX6.1 induced pluripotent stem cell reporter lines for isolation and analysis of functionally relevant neuronal and pancreas populations.
Journal: Stem cell research
Published: January 05, 2018
Decoding non-random mutational signatures at Cas9 targeted sites.
Journal: Nucleic acids research
Published: December 28, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026